Showing posts with label Stem Cell Therapy. Show all posts
Showing posts with label Stem Cell Therapy. Show all posts

Saturday, 19 January 2019

How stem cells self-organize in the developing embryo


Embryonic development is a process of profound physical transformation, one that has challenged researchers for centuries. How do genes and molecules control forces and tissue stiffness to orchestrate the emergence of form in the developing embryo? How are the precise mechanics underlying emergence of the complexity of our organs and tissues encoded in our DNA?

One particular aspect of embryonic development: how a group of stem cells -- the endoderm -- moves from the surface of the developing embryo to the center, and in doing so transforms from a flat sheet to a hollow tube. This structure, known as the gut tube, then forms the lining of the entire respiratory and gastrointestinal tracts.

In a study published today in Nature, Nerurkar worked with colleagues at Harvard to shed new light on this critical step in early embryonic development. The team discovered gut tube formation is driven by collective cell movements of the endoderm, a process by which cells travel large distances en masse, without rearranging relative to one another. They also found that this collective movement is triggered by cells that are converting a molecular gradient to a force gradient that drives cells from the surface into the embryo. This discovery is one of the few examples, especially among vertebrates, of how molecular cues are converted into the physical forces that shape our organs.
The study findings could have important implications for how stem cells are used to create functional organs in the lab, and lead to a better understanding of the underlying causes of gastrointestinal birth defects. "Our major goal is to understand how we, as complex organisms, are formed with such precision from a seemingly disorganized ball of cells -- the early embryo," says Nandan Nerurkar, assistant professor of biomedical engineering at Columbia Engineering.
Identifying genes that drive differentiation of stem cells into mature cell types -- the primary focus in Nerurkar's field -- is an important step toward growing replacement organs in the lab. However, Nerurkar suggests this is only part of the picture: "It is equally important to understand how to instruct those cells to organize into functional three-dimensional organs. The developing embryo holds the recipe for this, and many research groups, including ours, are now leveraging the language of physics and mechanics to dissect it."

The team used an innovative approach at the leading edge of the developmental biology field. They combined conventional approaches of developmental biology, including analysis and manipulation of gene expression and live time lapse microscopy of cell movements in the developing chick embryo, with engineering methods, such as mathematical modeling and force and strain measurements.

They focused on one part of endoderm internalization: the hindgut, which gives rise to half of the small intestine, the large intestine, and colon. What was previously known of gut tube formation came from fate-mapping experiments, wherein cells are labeled early in development and then mapped to where the labeled cells end up later in development. This static analysis, which uses static images of the beginning and the end of the process to make an educated guess of what happens in the middle, has led to a view of gut tube formation that is present in most embryology textbooks. "Based on our recent findings, this view is at best incomplete, and at worst completely wrong," says Nerurkar.

Unlike earlier fate-mapping studies, Nerurkar and his colleagues used live imaging in the embryo to directly observe cell movements as the endoderm is internalized to form a tube. They next applied a combination of mechanical engineering and developmental biology approaches to understand just how those cell movements occur, and how the movements are coordinated to form this critical structure in the early embryo.

The team found that the movements are coordinated by the conversion of a molecular gradient into a force gradient from cells that are contracting in proportion to the amount of a molecular cue -- fibroblast growth factor (FGF) -- that they sense. This results in a tug of war among endoderm cells: as one "team" begins to win, the cells actually recruit players from the opposing team by pulling them from low to higher concentrations of FGF.
Irregularities in FGF function can lead to a number of developmental defects. "During human development, errors in gut tube formation would likely lead to miscarriage, something that is a relatively high risk during the first trimester, when this process is occurring," says Nerurkar.
While this study focused on just one part of endoderm internalization, the hindgut, it is still unknown how the foregut, which forms the trachea, lungs, esophagus, stomach, and liver, and the midgut, which forms the pancreas and small intestine, are formed. Nerurkar plans to use his new approach to study these other areas of embryonic development and investigate if and how FGF signaling acts more broadly to control mechanics in the development of other tissues and organs.
"I want to learn more about how mechanics and molecules are integrated to coordinate the formation of these very distinct tissues by disparate mechanisms, yet from the same initial pool of stem cells," he says. "By focusing on the tissue-level mechanics downstream of FGF signaling, we may now be able to understand what this important pathway does to shape other organs and tissues during development, including the heart, brain, and spinal column."
Nerurkar is continuing this research at Columbia Engineering, developing quantitative molecular-mechanical relationships that could be used to design and construct replacement tissues in the lab, using controlled delivery of these diffusible cues -- the instructional signals that are secreted by cells and then float away to neighboring cells -- to instruct the self organization of cells into functional tissues and organs. If he and others in this field can establish the design principles of embryonic tissue formation, it will be possible to repurpose those same principles for regenerative medicine and tissue engineering applications.
Researchers from different part of the world are invited to submit abstract on their unpublished latest research at our upcoming conference Cell Tissue Science 2019 which is focused on the complications and consequences of Stem Cell, Regenerative Medicine, Stem Cell Therapy, Cancer Cell Biology,Technical Advancements in cancer treatment and many more. We as committee members of the conference welcome you to be a part of the conference “ 12th World Congress on Cell & Tissue Science” in Singapore on March 11-12, 2019. 
You can submit your abstract on Session or Track : 09. Stem Cells and its Applications

Tuesday, 11 December 2018

Potential seen for tailoring treatment for acute myeloid leukemia


Advances in rapid screening of leukemia cells for drug susceptibility and resistance are bringing scientists closer to patient-tailored treatment for acute myeloid leukemia (AML).

Research on the drug responses of leukemia stem cells may reveal why some attempts to treat are not successful or why initially promising treatment results are not sustained.

AML is a serious disorder of certain blood-forming cells. In this disease, certain early precursor cells in the bone marrow that usually develop into white blood cells don't mature properly. They remain frozen as primitive cells called blasts, unable to further differentiate and mature. These can accumulate and cause low blood counts that reduce the ability to fight infections, and low platelet counts that cause risk of life threatening hemorrhage.

Leukemia stem cells -- the progenitors for the immature, cancerous blood cells -- propagate AML, and also play a role in the cancer returning after treatment. Cancer researchers are interested in how genes are expressed in this cell population, because this data may hold clues to resistance to standard therapies and answers to why some patients relapse.

A study presented at the 60th Annual Meeting of the American Society of Hematology in San Diego looked at the drug response patterns of stem cells and blast cells taken from individual patients diagnosed with acute myeloid leukemia. The information was gathered through high throughput screening, a state of the art method for quickly evaluating and testing many samples.

The researchers found that leukemia stem cells and blast cells diverged in their drug susceptibility patterns, and also that these patterns differed from patient to patient.
For example: Blast cells s responded in the test to the drugs most commonly used to treat patients, but none were effective against leukemia stem cells. The researchers did find 12 drugs from eight classes that seemed to preferentially target leukemia stem cells, compared to blast cells. Many of them are not often used in patients with this type of cancer.
The multidisciplinary team on the project included stem cell biologists, hematologists, medical oncologists, pathologists, computer scientists, drug developers and others.

The senior researcher was hematologist Dr. Pamela Becker, professor of medicine at the UW School of Medicine. She is also a scientist at the Fred Hutchinson Cancer Research Center and the UW Medicine Institute for Stem Cells and Regenerative Medicine, and sees patients with blood disorders at the Seattle Cancer Care Alliance.

In the laboratory study, the researchers compared the drug sensitivity of blast cell and stem cell populations taken from the same six patients. In doing so, they tested a custom panel of drugs, targeted agents and drug combinations on the cells, and did genetic analyses for 194 mutations. The panel included both FDA approved and investigational drugs.

The unique drug susceptibility patterns observed in leukemia stem cells and blast cells are leading the scientists to hope that patient-specific approaches could be developed against acute myeloid leukemia, with the goal of improving the outcomes for people with this form of blood cancer.
We welcome researchers from different part of the to submit abstract on their latest research at our upcoming conference Cell Tissue Science 2019 which is mainly focuses on the complications the consequences of Stem Cell, Regenerative Medicine, Stem Cell Therapy, Cancer Cell Biology , Technical Advancements in cancer treatmentand many more.We welcome you to the our upcoming conference “ 12th World Congress on Cell & Tissue Science” . 
You can submit your abstract on Session or Track : 09. Stem Cells and its Applications

Friday, 7 December 2018

Platelets grown from stem cells may be alternative to donated platelets


Researchers have developed a way to grow human platelets in the laboratory from stem cells derived from fat tissue. The achievement, reported today in the Journal Blood, suggests manufactured platelets could eventually reduce the reliance on donated platelets to help patients with cancer and other disorders.

Platelets are a component of blood that helps with clotting. Platelet transfusions can be life-saving for patients dealing with cancer or the effects of chemotherapy, infections, immune disorders, or platelet disorders.

Over 4.5 million platelet units of plasma are transfused every year worldwide, a need that currently must be met by human donors. Because donated platelets have a shelf life of less than a week, supplies often fall short of patient needs. In addition, donated platelets are subject to inherent safety risks due to infection from the donor and immune response in the recipient.
"By removing the donor from the equation, adipose-derived stem cells could be used to provide a ready supply of safe, tolerable platelets to meet an ever-changing demand," said Dr. Mastubara.
Researchers initially sought to derive platelets from two other types of stem cells including one known as induced pluripotent stem cells (iPS). They noticed adipose-derived cells, which were being used as a negative control in the experiments, had produced megakaryocyte- and platelet-sized cells that naturally expressed several genes important to producing platelets.

After refining methods for coaxing adipose-derived stem cells to produce platelets, the researchers conducted a series of tests to determine whether the manufactured platelets would function similarly to natural human platelets. They verified that the lab-grown platelets contained hallmark proteins found on the surface of natural platelets, as well as granules that are key to the clotting process. Blood clotting simulations and experiments using mice confirmed that the platelets behave like donated platelets, gathering together into clumps to form clots.
"Though more expensive to harvest compared to donor-derived platelets, this research demonstrates that platelets can be produced from adipose-derived cells by a rather simple method," said Matsubara. "Now that we have established an efficient manufacturing process to yield a large number of adipose-derived platelets, we next plan to perform preclinical studies using animal models to demonstrate efficacy and safety, followed by clinical trials in human patients."
We welcome researchers from different part of the to submit abstract on their latest research at our upcoming conference Cell Tissue Science 2019 which is mainly focuses on the complications the consequences of Stem Cell, Regenerative Medicine, Stem Cell Therapy, Cancer Cell Biology , Technical Advancements in cancer treatmentand many more.We welcome you to the our upcoming conference “ 12th World Congress on Cell & Tissue Science” .  You can submit your abstract on Session or Track : 09. Stem Cells and its Applications

Tuesday, 6 November 2018

Advance stem cell therapy with biodegradable scaffold


181105081710_1_540x360
A biodegradable inorganic nano-scaffold, consisting of stem cells, proteins and drugs, for advanced stem cell therapy and drug delivery.
Credit: KiBum Lee, Letao Yang and Sy-Tsong Dean Chueng

Stem cell transplantation, which shows promise as a treatment for central nervous system diseases, has been hampered by low cell survival rates, incomplete differentiation of cells and limited growth of neural connections.

So, Rutgers scientists designed bio-scaffolds that mimic natural tissue and got good results in test tubes and mice, according to a study in Nature Communications. These nano-size scaffolds hold promise for advanced stem cell transplantation and neural tissue engineering. Stem cell therapy leads to stem cells becoming neurons and can restore neural circuits.
"It's been a major challenge to develop a reliable therapeutic method for treating central nervous system diseases and injuries," said study senior author KiBum Lee, Department of Chemistry and Chemical Biology at Rutgers University-New Brunswick. "Our enhanced stem cell transplantation approach is an innovative potential solution."
The researchers, in cooperation with neuroscientists and clinicians, plan to test the nano-scaffolds in larger animals and eventually move to clinical trials for treating spinal cord injury. The scaffold-based technology also shows promise for regenerative medicine.
We welcome researchers from different part of the world to submit your latest research at our upcoming conference “12th World Congress on Cell & Tissue Science” scheduled on March 11-12,2019 in Singapore which is mainly focuses on the complications the consequences of Stem Cell, Regenerative Medicine, Stem Cell Therapy, Cancer Cell Biology , Technical Advancements in cancer treatment and many more. For more info visit our conference website:Cell Tissue Science 2019